Ferumoxytol negatively enhances T 2 -weighted MRI of pedal osteomyelitis in vivo

Alex Neuwelt, Jens Langsjoen, Thomas Byrd, Stephen Eberhardt, Gary Mlady, Justin Baca, Therese Bocklage, Cathleen Martinez, Jonathan Orner, Marisa Rivera, Laurel O. Sillerud

Research output: Contribution to journalLetterpeer-review

7 Scopus citations
Original languageEnglish
Pages (from-to)1241-1245
Number of pages5
JournalJournal of Magnetic Resonance Imaging
Volume45
Issue number4
DOIs
StatePublished - Apr 1 2017

Funding

This project was supported in part by grants from AMAG Pharmaceuticals, Inc., and the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1 TR001449). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or AMAG Pharmaceuticals. We also thank the Clinical Translational Science Center staff at the University of New Mexico for their tireless dedication to the support of this research.

FundersFunder number
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)UL1TR001449
New Mexico State University, New York University
Center for Clinical and Translational Science, Mayo Clinic
AMAG Pharmaceuticals, Inc

    Keywords

    • Ferumoxytol
    • osteomyelitis
    • superparamagnetic iron oxide nanoparticle

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging

    Fingerprint

    Dive into the research topics of 'Ferumoxytol negatively enhances T 2 -weighted MRI of pedal osteomyelitis in vivo'. Together they form a unique fingerprint.

    Cite this